Controlled Substance NDAs Face Extra DEA Review Beginning In June
Executive Summary
The Drug Enforcement Administration will begin reviewing controlled substance NDAs and ANDAs under new legislative language scheduled to take effect June 6
You may also be interested in...
Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
Duragesic Risk Management Negotiations Ongoing After FDA Health Advisory
Creation of a risk management plan for Johnson & Johnson's Duragesic and generics could be the next regulatory step for the product after FDA's release of a Public Health Advisory on fentanyl overdoses
Pfizer Lyrica Launch Awaits Controlled Substance Scheduling
Pfizer's launch of Lyrica will be delayed while pregabalin undergoes controlled substance scheduling at the Drug Enforcement Administration